From May 30 to June 3, 2025, the largest global oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, was held in Chicago, USA. Researchers including Philippe Armand presented data from the waveLINE-003 Phase II study, exploring the recommended treatment dose, safety, and efficacy of the novel antibody-drug conjugate (ADC) Zilovertamab vedotin (ZV) … Read more
Company Overview MediLink Therapeutics was founded in 2020, headquartered in Suzhou (with a research branch in Boston, USA), and has established research institutions in Shanghai and Singapore. The company’s founder, Dr. Xue Tongtong, previously served as the general manager of Kelun-Biotech and has over 10 years of experience in the research and management of antibodies, … Read more
Click the blue text Follow us This Issue Focus Point B7-H4 is a member of the B7 immune checkpoint ligand family, which has been shown to bind to an unknown receptor on T cells, inhibiting T cell proliferation and cytokine production, thereby negatively regulating T cell function. The expression level of B7-H4 is elevated in … Read more
The abstract from AACR hides a new modality. Following yesterday’s TCE conjugated ADC, there is also the Triple-payload ADC project submitted by Araris. Currently, only the abstract has been released, indicating that this is an ADC molecule targeting Nectin-4, designed with MMAE and dual Topo1i as a triple payload. Below is the full abstract:Araris’s site-specific … Read more
GUIDE Editor’s Recommendation Antibody-drug conjugates (ADC) remained popular in 2022. Enhertu redefined the treatment landscape for HER2 breast cancer, making headlines at major academic conferences like ASCO and ESMO; Kelun-Biotech approached a $10 billion license-out deal with multinational pharmaceutical company Merck, setting a new record for local pharmaceutical companies going abroad; the world’s first anti-CD79b … Read more
Medical researchers are not only continuously developing new anti-tumor drugs but are also trying to find new uses for old drugs, hoping to alleviate the suffering caused by cancer and extend survival. High-dose vitamin C treatment for cancer is one of these methods, which is still under research. Many people may wonder how vitamin C, … Read more
Compiled by: Oncology News Source: Oncology News PET/CT has currently been recommended for imaging assessment at the initial diagnosis of multiple myeloma (MM) patients, as well as for evaluating the efficacy after treatment. In recent years, with the application of new drugs and autologous stem cell transplantation (ASCT), it has become possible for MM patients … Read more
Organized by: Oncology Information Source: Oncology Information Recently, a prospective study published by Professor Zhang Mingzhi, Professor Chen Qingjiang, and Professor Zhang Xudong from Zhengzhou University First Affiliated Hospital in Frontiers in Oncology (impact factor 6.244) evaluated the efficacy and safety of decitabine (DAC) combined with cisplatin, cytarabine, and dexamethasone (DHAP) modified regimen in patients … Read more
Currently, there are 15 ADC drugs approved globally, among which 6 ADC drugs have been approved in China, namely Trastuzumab emtansine, Brentuximab vedotin, Trastuzumab deruxtecan, Vidofludimus, Gemtuzumab ozogamicin, and Sacituzumab govitecan. This article provides a brief summary based on the currently approved ADC drugs worldwide, the types of tumors they are suitable for, and how … Read more
In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that drugs could be developed to specifically target pathogenic structures without harming normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target specificity of monoclonal antibodies with the anti-tumor properties of cytotoxic molecules. After … Read more